← Leaderboards
Nita A Limdi
University Of Alabama At Birmingham
$16,814,616
Attributed
$21,233,794
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,233,794 · 5
By mechanism
R01$10,406,607 · 1
U01$8,406,723 · 1
K24$1,194,040 · 1
K23$794,790 · 1
T32$431,634 · 1
Top collaborators
- James J. Cimino8 shared
- Gregory S. Barsh1 shared
- Gregory Michael Cooper1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jennifer S Guimbellot$2,518,311
- Brittney H Davis$338,360
Others in their field
Top investigators on “Genotype”
- David R. Weir · University Of Michigan At Ann Arbor$303,033,420
- Richard A Gibbs · Baylor College Of Medicine$211,329,145
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Stacey Gabriel · Massachusetts Institute Of Technology$153,486,482
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$141,132,078
Research focus
GenotypeHemorrhageCohortWarfarinResponseGeneticAfrican AmericanAnticoagulationDosePharmaceutical PreparationsEuropeanGenomicsGenesRaceProspectiveAccountingVariantCandidate Disease GeneBaseAmericanFoundationsComorbidityMorbidity - Disease RateAlabama
Grant awards (41)
Integrating Genomic Risk Assessment for Disease Management in a Clinical Population$860,431
U01 · FY2025 · HG · contact PI
UAB-HudsonAlpha Genomic Medicine Training Program$344,728
T32 · FY2025 · HG · contact PI
Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy$120,424
K24 · FY2025 · HL · contact PI
Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population$1,082,151
U01 · FY2024 · HG · contact PI
Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy$120,424
K24 · FY2024 · HL · contact PI
UAB-HudsonAlpha Genomic Medicine Training Program$86,906
T32 · FY2024 · HG · contact PI
Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population$1,484,587
U01 · FY2023 · HG · contact PI
Predictors of hemorrhage among patients on direct acting oral anticoagulants$729,872
R01 · FY2023 · HL · contact PI
Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population$340,002
U01 · FY2023 · HG · contact PI
Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy$120,424
K24 · FY2023 · HL · contact PI
Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population$1,603,153
U01 · FY2022 · HG · contact PI
Predictors of hemorrhage among patients on direct acting oral anticoagulants$731,850
R01 · FY2022 · HL · contact PI
Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population$144,382
U01 · FY2022 · HG · contact PI
Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy$120,424
K24 · FY2022 · HL · contact PI
Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population$1,633,230
U01 · FY2021 · HG · contact PI
Predictors of hemorrhage among patients on direct acting oral anticoagulants$732,370
R01 · FY2021 · HL · contact PI
Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy$120,424
K24 · FY2021 · HL · contact PI
Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population$1,258,787
U01 · FY2020 · HG · contact PI
Predictors of hemorrhage among patients on direct acting oral anticoagulants$742,075
R01 · FY2020 · HL · contact PI
Patient Oriented Research in Personalized Antithrombotic Therapy$118,384
K24 · FY2020 · HL · contact PI
Patient Oriented Research in Personalized Antithrombotic Therapy$118,384
K24 · FY2019 · HL · contact PI
Genetic and Clinical Predictors of Response to Warfarin and Novel Anticoagulants$711,488
R01 · FY2018 · HL · contact PI
Patient Oriented Research in Personalized Antithrombotic Therapy$118,384
K24 · FY2018 · HL · contact PI
Genetic and Clinical Predictors of Response to Warfarin and Novel Anticoagulants$711,004
R01 · FY2017 · HL · contact PI
Patient Oriented Research in Personalized Antithrombotic Therapy$118,384
K24 · FY2017 · HL · contact PI
Genetic and Clinical Predictors of Response to Warfarin and Novel Anticoagulants$719,078
R01 · FY2016 · HL · contact PI
Patient Oriented Research in Personalized Antithrombotic Therapy$118,384
K24 · FY2016 · HL · contact PI
Genetic and Clinical Predictors of Response to Warfarin and Novel Anticoagulants$684,219
R01 · FY2015 · HL · contact PI
Genetic and Clinical Predictors of Response to Warfarin and Novel Anticoagulants$704,923
R01 · FY2014 · HL · contact PI
Genetic and Environmental Determinants of Warfarin Response$712,940
R01 · FY2012 · HL · contact PI
Genetic and Environmental Determinants of Warfarin Response$705,285
R01 · FY2011 · HL · contact PI
Genetic and Environmental Determinants of Warfarin Response$713,486
R01 · FY2010 · HL · contact PI
Genetic and Environmental Determinants of Warfarin Response$726,187
R01 · FY2009 · HL · contact PI
Genetic and Environmental Determinants of Warfarin Response$332,781
R01 · FY2009 · HL · contact PI
Genetic and Environmental Determinants of Warfarin Response$15,777
R01 · FY2009 · HL · contact PI
Genetic and Environmental Determinants of Warfarin Response$733,272
R01 · FY2008 · HL · contact PI
Pharmacogenetic Optimization of Anticoagulation Therapy$158,958
K23 · FY2007 · NS · contact PI
Pharmacogenetic Optimization of Anticoagulation Therapy$158,958
K23 · FY2006 · NS · contact PI
Pharmacogenetic Optimization of Anticoagulation Therapy$158,958
K23 · FY2005 · NS
Pharmacogenetic Optimization of Anticoagulation Therapy$158,958
K23 · FY2004 · NS
Pharmacogenetic Optimization of Anticoagulation Therapy$158,958
K23 · FY2003 · NS